This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
by Zacks Equity Research
Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.
Is Lantheus (LNTH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
bluebird (BLUE) Down on Updates on SCD Therapy, Reports Q4
by Zacks Equity Research
bluebird (BLUE) provides updates on its BLA submission for its experimental gene therapy lovo-cel and reports Q4 results. Shares are down on the same.
Here's Why Investors Should Hold Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, continuous pursuit of acquisitions and commendable financial position.
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
Only Electric Autos in 10 Years' Time?
by John Blank
And a few more macroeconomic thoughts, along with that.
Viking (VKTX) Announces Clinical Data for Metabolic Disorders
by Zacks Equity Research
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $155.32, marking a +0.4% move from the previous day.
Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU
by Zacks Equity Research
Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Novo Nordisk (NVO) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novartis (NVS) Kisqali Positive for Early Breast Cancer
by Zacks Equity Research
Novartis (NVS) Kisqali meets primary endpoint of invasive disease-free survival in certain patients with early breast cancer at risk of recurrence.
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal
by Zacks Equity Research
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Beat the Market Like Zacks: NVIDIA, SoundHound, Reuters in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment
by Zacks Equity Research
Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
by Zacks Equity Research
The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
by Zacks Equity Research
In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951.
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
by Zacks Equity Research
Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
The Zacks Analyst Blog Highlights Amazon.com, Novo Nordisk, Qualcomm, Booking Holdings and Chubb
by Zacks Equity Research
Amazon.com, Novo Nordisk, Qualcomm, Booking Holdings and Chubb are part of the Zacks top Analyst Blog.
Novo Nordisk (NVO) Stock Moves -0.41%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $146.69, marking a -0.41% move from the previous day.
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
by Zacks Equity Research
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.
Top Stock Reports for Amazon.com, Novo Nordisk & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Novo Nordisk A/S (NVO) and QUALCOMM Incorporated (QCOM).
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.